Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®

Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG... Aims/hypothesis The global epidemic of type 2 diabetes affects women and men equally; however, the relative impact on the cardiovascular (CV) system appears greater for women than men when compared with peers without diabetes. Furthermore, women are often under-represented in CVoutcome trials, resulting in less certainty about the impact of CV prevention therapies across the sexes. The EMPA-REG OUTCOME® trial, which included 28.5% women, found that empagliflozin, given in addition to standard of care, reduced the risk of CV death by 38%, heart failure (HF) hospitalisation by 35% and a composite endpoint for incident or worsening nephropathy by 39%. Here we report a secondary analysis of the trial to determine the relative effects of empagliflozin in women vs men. Methods The population studied were individuals with type 2 diabetes (HbA 53–86 mmol/mol [7–10%] and eGFR 1c −1 −2 >30 ml min [1.73 m] ), with established atherosclerotic CV disease. Individuals were randomised to receive empagliflozin 10 mg or 25 mg, or placebo once daily in addition to standard of care, and followed. The trial continued until ≥691 individuals had experienced an adjudicated event included in the primary outcome. All CV outcome events, including HF hospitalisations and deaths were prospectively http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetologia Springer Journals

Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®

Download PDF
6 pages

Loading next page...
 
/lp/springer_journal/empagliflozin-in-women-with-type-2-diabetes-and-cardiovascular-disease-d7q0TfWWcz
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Internal Medicine; Metabolic Diseases; Human Physiology
ISSN
0012-186X
eISSN
1432-0428
DOI
10.1007/s00125-018-4630-2
pmid
29713728
Publisher site
See Article on Publisher Site

Abstract

Aims/hypothesis The global epidemic of type 2 diabetes affects women and men equally; however, the relative impact on the cardiovascular (CV) system appears greater for women than men when compared with peers without diabetes. Furthermore, women are often under-represented in CVoutcome trials, resulting in less certainty about the impact of CV prevention therapies across the sexes. The EMPA-REG OUTCOME® trial, which included 28.5% women, found that empagliflozin, given in addition to standard of care, reduced the risk of CV death by 38%, heart failure (HF) hospitalisation by 35% and a composite endpoint for incident or worsening nephropathy by 39%. Here we report a secondary analysis of the trial to determine the relative effects of empagliflozin in women vs men. Methods The population studied were individuals with type 2 diabetes (HbA 53–86 mmol/mol [7–10%] and eGFR 1c −1 −2 >30 ml min [1.73 m] ), with established atherosclerotic CV disease. Individuals were randomised to receive empagliflozin 10 mg or 25 mg, or placebo once daily in addition to standard of care, and followed. The trial continued until ≥691 individuals had experienced an adjudicated event included in the primary outcome. All CV outcome events, including HF hospitalisations and deaths were prospectively

Journal

Diabetologia – Springer Journals

Published: Apr 30, 2018

References

  • Sex-specific differential in risk of diabetes-related macrovascular outcomes
    Lyon, A; Jackson, EA; Kalyani, RR; Vaidya, D; Kim, C
  • Status of women in cardiovascular clinical trials
    Kim, ES; Menon, V
  • Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes: CAROLINA®
    Marx, N; Rosenstock, J; Kahn, SE
  • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    Zinman, B; Wanner, C; Lachin, JM
  • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, D; Zinman, B; Wanner, C
  • Empagliflozin and progression of kidney disease in type 2 diabetes
    Wanner, C; Inzucchi, SE; Lachin, JM
  • Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalisation across the spectrum of heart failure risk in the EMPA-REG OUTCOME® Trial
    Fitchett, D; Butler, J; Borne, P
  • Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
    Devi, R; Mali, G; Chakraborty, I; Unnikrishnan, MK; Abdulsalim, S